ArticleAnalytical and bioanalytical chemistry2019
Intraoperative detection of isocitrate dehydrogenase mutations in human gliomas using a miniature mass spectrometer.
Article in Analytical and bioanalytical chemistry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 28 citations in OpenAlex.
- Metabolite ratiomics: Rapid diagnosis and classification of gliomas for intraoperative application during brain surgery.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Isocitrate Dehydrogenase Mutation Assessment in Human Glioma Using Desorption Electrospray Ionization-Multiple Reaction Monitoring.Analytical chemistry · 2026Article
- Ambient ionization mass spectrometry in brain cancer diagnosis.Journal of mass spectrometry and advances in the clinical lab · 2025Review
- Development and multicenter validation of on-site breast cancer diagnosis using paper spray ionization miniature mass spectrometry.Communications medicine · 2025Article
- Advancing Glioma Management: The Pivotal Role of Surgical Neuro-Oncology in Driving Innovation and Translational Research.Current oncology reports · 2025Review
- Detection of IDH mutation in glioma by desorption electrospray ionization (DESI) tandem mass spectrometry.Scientific reports · 2024Article
- Rapid detection of IDH mutations in gliomas by intraoperative mass spectrometry.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Recent advances in the detection of glioblastoma, from imaging-based methods to proteomics and biosensors: A narrative review.Cancer cell international · 2023Review
- Miniature mass spectrometer-based point-of-care assay for measuring phosphatidylethanol in blood.The Analyst · 2023Article
- Portable mass spectrometry system: instrumentation, applications, and path to 'omics analysis.Proteomics · 2022Review
- High-throughput analysis of tissue microarrays using automated desorption electrospray ionization mass spectrometry.Scientific reports · 2022Article
- Miniature mass spectrometer-based point-of-care assay for cabotegravir and rilpivirine in whole blood.Analytical and bioanalytical chemistry · 2022Article
- Recent advances in on-site mass spectrometry analysis for clinical applications.Trends in analytical chemistry : TRAC · 2022Review
- Metabolomic Phenotyping of Gliomas: What Can We Get with Simplified Protocol for Intact Tissue Analysis?Cancers · 2022Article
- Novel Ion Trap Scan Modes to Develop Criteria for On-Site Detection of Sulfonamide Antibiotics.Analytical chemistry · 2021Article
- Metabolic profiles of human brain parenchyma and glioma for rapid tissue diagnosis by targeted desorption electrospray ionization mass spectrometry.Analytical and bioanalytical chemistry · 2021Article
- Glioblastoma Metabolomics-In Vitro Studies.Metabolites · 2021Review
- Challenges and Perspectives of Standard Therapy and Drug Development in High-Grade Gliomas.Molecules (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 2 countries.
Funding
Abstract
Knowledge of the isocitrate dehydrogenase (IDH) mutation status of glioma patients could provide insights for decision-making during brain surgery. However, pathology is not able to provide such information intraoperatively. Here we describe the first application of a miniature mass spectrometer (MS) to the determination of IDH mutation status in gliomas intraoperatively. The instrumentation was modified to be compatible with use in the operating room. Tandem MS was performed on the oncometabolite, 2-hydroxyglutarate, and a reference metabolite, glutamate, which is not involved in the IDH mutation. Ratios of fragment ion intensities were measured to calculate an IDH mutation score, which was used to differentiate IDH mutant and wild-type tissues. The results of analyzing 25 biopsies from 13 patients indicate that reliable determination of IDH mutation status was achieved (p = 0.0001, using the Kruskal-Wallis non-parametric test). With its small footprint and low power consumption and noise level, this application of miniature mass spectrometers represents a simple and cost-effective platform for an important intraoperative measurement. Graphical abstract.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.